Cabaletta Bio (CABA) Stock Forecast & Price Target

$2.27 -0.02 (-0.87%)

(As of 12:15 PM ET)

Cabaletta Bio - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Cabaletta Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 1 has given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for CABA.

Consensus Price Target

$24.38
973.79% Upside

According to the 9 analysts' twelve-month price targets for Cabaletta Bio, the average price target is $24.38. The highest price target for CABA is $50.00, while the lowest price target for CABA is $6.00. The average price target represents a forecasted upside of 973.79% from the current price of $2.27.

Get the Latest News and Ratings for CABA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cabaletta Bio and its competitors.

CABA Analyst Ratings Over Time

Type	Current Forecast 12/31/23 to 12/30/24	1 Month Ago 12/1/23 to 11/30/24	3 Months Ago 10/2/23 to 10/1/24	1 Year Ago 12/31/22 to 12/31/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$24.38	$26.25	$30.11	$27.64
Forecasted Upside	973.79% Upside	587.17% Upside	548.95% Upside	21.75% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Kamala’s final humiliation (Ad)

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

CABA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CABA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cabaletta Bio Stock vs. The Competition

Type	Cabaletta Bio	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	978.54% Upside	24,315.74% Upside	15.67% Upside
News Sentiment Rating	Positive News See Recent CABA News	Positive News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	Evercore ISI 2 of 5 stars	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$15.00 ➝ $6.00	+159.74%
12/19/2024	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$12.00 ➝ $6.00	+162.01%
11/29/2024	TD Cowen 5 of 5 stars	M. Frahm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/18/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
11/15/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00	+561.37%
10/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Huynh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00	+141.55%
Get the Latest News and Ratings for CABA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.
6/21/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00	+459.28%
6/17/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00	+227.20%
4/4/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$26.00 ➝ $30.00	+80.40%
2/5/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+63.41%
11/29/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$28.00 ➝ $25.00	+66.22%
8/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$34.00	+151.11%
3/22/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$12.00	+55.24%
3/17/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$10.00	+29.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:20 PM ET.

CABA Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Cabaletta Bio is $24.38, with a high forecast of $50.00 and a low forecast of $6.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There is currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares.
: According to analysts, Cabaletta Bio's stock has a predicted upside of 973.79% based on their 12-month stock forecasts.
: Over the previous 90 days, Cabaletta Bio's stock had 2 downgrades and 1 upgrade by analysts.
: Cabaletta Bio has been rated by research analysts at Evercore ISI, HC Wainwright, TD Cowen, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Cabaletta Bio more than other "medical" companies. The consensus rating for Cabaletta Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CABA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Altcoin season moves fast, and those who hesitate are left behind. The window is closing.

>> Register for the Workshop Now

This page (NASDAQ:CABA) was last updated on 12/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Stock Forecast & Price Target